TrialJournal of substance abuse treatment2008

Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors.

Lynn E Sullivan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.